SEARCH:   Advanced

Blood, 15 May 2007, Vol. 109, No. 10, pp. 4441-4449. Prepublished online as a Blood First Edition Paper on January 16, 2007; DOI 10.1182/blood-2006-07-034173. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-07-034173v1 109/10/4441    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Pérez-Galán, P. Articles by Colomer, D. Search for Related Content PubMed PubMed Citation Articles by Pérez-Galán, P. Articles by Colomer, D. Related Collections Immunobiology Neoplasia Apoptosis Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak Patricia Pérez-Galán1, Gaël Roué1, Neus Villamor1, Elias Campo1, and Dolors Colomer1 1 Hematopathology Unit, Department of Pathology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma resistant to conventional chemotherapy. The Bcl-2 pathway is deregulated in these tumors and may represent an interesting target for new therapeutic strategies. The new small-molecule pan–Bcl-2 inhibitor GX15-070 mimics BH3-only proteins by binding to multiple antiapoptotic Bcl-2 members. Here we show that GX15-070 induced apoptosis in vitro in MCL cell lines and primary cells from patients with MCL by releasing Bak from Mcl-1 and Bcl-XL at short incubation times and low micromolar doses. GX15-070 was effective in cells bearing defective DNA damage-sensor genes or cell-cycle regulators, inducing Bax and Bak conformational changes, mitochondrial depolarization, phosphatidylserine exposure, and caspase-3 activation. Furthermore, GX15-070 synergized with bortezomib, sensitizing MCL cells to low doses of this proteasome inhibitor, by neutralizing bortezomib-induced Mcl-1 accumulation and cooperating with Noxa to induce Bak displacement from this protein. These events led to an increased activation of the mitochondrial apoptotic pathway. Importantly, GX15-070 alone or in combination with bortezomib showed no significant cytotoxic effect in peripheral blood mononuclear cells from healthy donors. All these findings suggest that GX15-070 alone or in combination with bortezomib represents a new attractive therapeutic approach for MCL treatment. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. L. Hurwitz, F. McCoy, P. Scullin, and D. A. Fennell New Advances in the Second-Line Treatment of Small Cell Lung Cancer Oncologist, October 1, 2009; 14(10): 986 - 994. [Abstract] [Full Text] [PDF] M. Lopez-Guerra, G. Roue, P. Perez-Galan, R. Alonso, N. Villamor, E. Montserrat, E. Campo, and D. Colomer p65 Activity and ZAP-70 Status Predict the Sensitivity of Chronic Lymphocytic Leukemia Cells to the Selective I{kappa}B Kinase Inhibitor BMS-345541 Clin. Cancer Res., April 15, 2009; 15(8): 2767 - 2776. [Abstract] [Full Text] [PDF] S. Bea, I. Salaverria, L. Armengol, M. Pinyol, V. Fernandez, E. M. Hartmann, P. Jares, V. Amador, L. Hernandez, A. Navarro, et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling Blood, March 26, 2009; 113(13): 3059 - 3069. [Abstract] [Full Text] [PDF] Q. Wang, H. Mora-Jensen, M. A. Weniger, P. Perez-Galan, C. Wolford, T. Hai, D. Ron, W. Chen, W. Trenkle, A. Wiestner, et al. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells PNAS, February 17, 2009; 106(7): 2200 - 2205. [Abstract] [Full Text] [PDF] M. H. Kang and C. P. Reynolds Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy Clin. Cancer Res., February 15, 2009; 15(4): 1126 - 1132. [Abstract] [Full Text] [PDF] Y. Tabe, D. Sebasigari, L. Jin, M. Rudelius, T. Davies-Hill, K. Miyake, T. Miida, S. Pittaluga, and M. Raffeld MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma Clin. Cancer Res., February 1, 2009; 15(3): 933 - 942. [Abstract] [Full Text] [PDF] S. M. O'Brien, D. F. Claxton, M. Crump, S. Faderl, T. Kipps, M. J. Keating, J. Viallet, and B. D. Cheson Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia Blood, January 8, 2009; 113(2): 299 - 305. [Abstract] [Full Text] [PDF] S. Huang, K. Okumura, and F. A. Sinicrope BH3 Mimetic Obatoclax Enhances TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells Clin. Cancer Res., January 1, 2009; 15(1): 150 - 159. [Abstract] [Full Text] [PDF] L. Shen, W.-Y. Au, K.-Y. Wong, N. Shimizu, J. Tsuchiyama, Y.-L. Kwong, R. H. Liang, and G. Srivastava Cell death by bortezomib-induced mitotic catastrophe in natural killer lymphoma cells Mol. Cancer Ther., December 1, 2008; 7(12): 3807 - 3815. [Abstract] [Full Text] [PDF] L. Paoluzzi, M. Gonen, G. Bhagat, R. R. Furman, J. R. Gardner, L. Scotto, V. D. Gueorguiev, M. L. Heaney, K. Manova, and O. A. O'Connor The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies Blood, October 1, 2008; 112(7): 2906 - 2916. [Abstract] [Full Text] [PDF] B. D. Zeitlin, I. J. Zeitlin, and J. E. Nor Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents J. Clin. Oncol., September 1, 2008; 26(25): 4180 - 4188. [Abstract] [Full Text] [PDF] V. F. Tumilasci, S. Oliere, T. L.-A. Nguyen, A. Shamy, J. Bell, and J. Hiscott Targeting the Apoptotic Pathway with BCL-2 Inhibitors Sensitizes Primary Chronic Lymphocytic Leukemia Cells to Vesicular Stomatitis Virus-Induced Oncolysis J. Virol., September 1, 2008; 82(17): 8487 - 8499. [Abstract] [Full Text] [PDF] J. L. Mott, S. F. Bronk, R. A. Mesa, S. H. Kaufmann, and G. J. Gores BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis Mol. Cancer Ther., August 1, 2008; 7(8): 2339 - 2347. [Abstract] [Full Text] [PDF] C. Li, R. Li, J. R. Grandis, and D. E. Johnson Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells Mol. Cancer Ther., June 1, 2008; 7(6): 1647 - 1655. [Abstract] [Full Text] [PDF] S. Huang and F. A. Sinicrope BH3 Mimetic ABT-737 Potentiates TRAIL-Mediated Apoptotic Signaling by Unsequestering Bim and Bak in Human Pancreatic Cancer Cells Cancer Res., April 15, 2008; 68(8): 2944 - 2951. [Abstract] [Full Text] [PDF] N. N. Danial BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death Clin. Cancer Res., December 15, 2007; 13(24): 7254 - 7263. [Abstract] [Full Text] [PDF] M. Nguyen, R. C. Marcellus, A. Roulston, M. Watson, L. Serfass, S. R. Murthy Madiraju, D. Goulet, J. Viallet, L. Belec, X. Billot, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis PNAS, December 4, 2007; 104(49): 19512 - 19517. [Abstract] [Full Text] [PDF] O. A. O'Connor Mantle Cell Lymphoma: Identifying Novel Molecular Targets in Growth and Survival Pathways Hematology, January 1, 2007; 2007(1): 270 - 276. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020